# Using functional readouts from engineering models of innervated skeletal muscle to assess the efficacy of CRISPR-based c9orf72 ALS gene therapies

> **NIH NIH R03** · UNIVERSITY OF WASHINGTON · 2022 · $88,250

## Abstract

PROJECT SUMMARY/ABSTRACT
Gene therapies employing CRISPR-Cas9-mediated genetic editing techniques have the potential to cure a wide
range of inheritable disorders, including amyotrophic lateral sclerosis (ALS). However, identifying edits capable
of neutralizing disease-causing mutations is a pressing issue. A critical bottleneck in the translation of novel gene
therapies to clinical trials is a lack of human models capable of producing functional metrics that correlate with
patient outcomes and provide predictive data with which to guide subsequent in vivo experiments. For ALS and
other neuromuscular disorders, the complexity associated with generating mature and functionally competent
neuromuscular junctions (NMJs) in culture with sufficient throughput for screening purposes is a major hindrance
to this effort. The development of a multiplexed platform capable of promoting NMJ development across a parallel
array of engineered muscle tissues will have a substantial positive impact on advanced therapy development,
drug efficacy/toxicity screening, and mechanistic studies of neuronal and NMJ pathophysiology in ALS. Building
on the PI’s work as a KL2 scholar, this project seeks to combine optogenetic motor neurons derived from ALS
patient induced pluripotent stem cells (iPSCs) with a magnet-based sensing platform for non-invasively detecting
engineered muscle contractions to establish a system for real-time, continuous assessment of NMJ functional
decline in ALS (Aim 1). Tests with cholinergic synaptic agonists and antagonists, in terms of their ability to alter
synaptic communication between cultured muscle and neurons, will be used to demonstrate the suitability of this
model for assaying changes in NMJ function in vitro. Once optimized, the described system will be used to
investigate multiple gene editing strategies for restoring function in C9orf72-mutant ALS; the most common
inheritable form of the disorder (Aim 2). ALS patient iPSC-derived motor neurons subjected to either bi-allelic
repeat excision or allele-specific C9orf72 gene inactivation will be compared for their ability to maintain NMJ
function over time in co-culture with engineered muscle tissues. The non-invasive nature of our magnetic sensing
system enables continuous assessment of muscle performance in response to optogenetically-controlled
neuronal activation, thereby enabling longitudinal study of therapeutic efficacy and parallel assessment of
multiple tissues subjected to different treatment regimens. Results from these experiments will provide a
framework for further preclinical validation of novel therapies targeting peripheral neuropathic diseases as well
as data to aid in the selection of which gene editing technique has the best chance of success in C9orf72 ALS
patients. Validation of the technologies outlined in this proposal will represent the culmination of work started by
the PI as part of the KL2 program and will form the core of the PI’s independent research going ...

## Key facts

- **NIH application ID:** 10497661
- **Project number:** 1R03TR004009-01A1
- **Recipient organization:** UNIVERSITY OF WASHINGTON
- **Principal Investigator:** Alec Simon Tulloch Smith
- **Activity code:** R03 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $88,250
- **Award type:** 1
- **Project period:** 2022-07-01 → 2024-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10497661

## Citation

> US National Institutes of Health, RePORTER application 10497661, Using functional readouts from engineering models of innervated skeletal muscle to assess the efficacy of CRISPR-based c9orf72 ALS gene therapies (1R03TR004009-01A1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10497661. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*